Novo Nordisk sues rival Eli Lilly over 'misleading' weight-loss drug advertising

Nbcwashington · 🇺🇸 public United States · Jul 22, 2026 · 519 words · By Maria Toledo Flores

headphones Listen to the eFinder podcast briefing

Generate a natural audio summary of this story

Daily briefing

What to know about Novo Nordisk sues rival Eli Lilly over 'misleading' weight-loss drug advertising

Two of the world's biggest pharmaceutical companies are headed to court after Novo Nordisk, the maker of Ozempic and a pioneer in diabetes and obesity treatments, sued rival Eli Lilly on Tuesday, accusing the U.S.

Claims checked 10

Techniques found 0

Topics 0

Coverage spectrum

Coverage gap: Low Left coverage

Left0%

Center80%

Right20%

5 sources compared across this story cluster. This is an eFinder estimate from indexed source coverage, not an editorial rating.

What happened

Why it matters

District Court in New Jersey, alleging Eli Lilly's advertising misled "millions of Americans living with obesity and type 2 diabetes" and violated federal and state false advertising and unfair competition laws.

Common ground

Stream NBC4 newscasts for free right here, right now.

Perspective signals

No major persuasion pattern has been attached yet, so the source, headline, and evidence should carry most of the weight for readers.

Follow-up questions

What concrete event or decision sits underneath the headline: Novo Nordisk sues rival Eli Lilly over 'misleading' weight-loss drug advertising?
What evidence would most clearly confirm or weaken the claim that Novo Nordisk, however, argues that Eli Lilly's advertising ignores newer evidence from the STEP UP trial, a 72-week study that evaluated a higher 7.2 mg dose of Wegovy?
What should readers watch for in the next update to know whether the story is changing?

open_in_new Read the original article: https://www.nbcwashington.com/news/health/novo-nordisk-sues-eli-lilly-over-misle…

fact_checkClaims Checked

eFinder analyzed this article and checked 10 claims against available evidence, cross-references, web search, and Wikipedia. Here is what the fact-checking layer found.

check_circle Corroborated 7

help Insufficient Evidence 2

verified Verified 1

help

Claim 1: “Novo Nordisk, however, argues that Eli Lilly's advertising ignores newer evidence from the STEP UP trial, a 72-week study that evaluated a higher 7.2 mg dose of Wegovy.”

INSUFFICIENT EVIDENCE

No evidence was found in the provided search results regarding a 'STEP UP trial' or a 72-week study evaluating a 7.2 mg dose of Wegovy.

check_circle

Claim 2: “Novo Nordisk claims Eli Lilly's advertising campaigns for Mounjaro and Zepbound, injectable medications used to help regulate blood sugar and appetite, intentionally relied on outdated studies that compared Eli Lilly's highest doses with lower doses of Novo Nordisk's medicines.”

CORROBORATED

Reports from NBC and other sources confirm Novo Nordisk's allegation that Lilly used outdated studies comparing high doses of Lilly's drugs to lower doses of Novo's.

menu_book

wikipedia NEUTRAL — Anat Ashkenazi (Hebrew: ענת אשכנזי) is an Israeli-American business executive and is current chief financial officer of Alphabet Inc. and its subsidiary Google. She had previously worked at Eli Lilly…
https://en.wikipedia.org/wiki/Anat_Ashkenazi

menu_book

wikipedia NEUTRAL — Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in appro…
https://en.wikipedia.org/wiki/Eli_Lilly_and_Company

menu_book

wikipedia NEUTRAL — Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd. Novo Nordisk is controlled by majority shareholder Novo Holdings A/S (wholly owned by the Novo Nordisk Foun…
https://en.wikipedia.org/wiki/Novo_Nordisk

+ 3 more evidence sources

check_circle

Claim 3: “The highest FDA-approved dose of Wegovy, as of March 2026, is 7.2 mg.”

CORROBORATED

Multiple sources confirm the FDA approved a 7.2 mg dose of Wegovy on March 19, 2026, making it the highest approved dose.

menu_book

wikipedia NEUTRAL — Roman Health Ventures Inc., doing business as Ro, is an American telehealth company that diagnoses patients, and subsequently prescribes and delivers treatments and ongoing care. The company is headqu…
https://en.wikipedia.org/wiki/Ro_(company)

menu_book

wikipedia NEUTRAL — Semaglutide is an anti-diabetic medication used for the treatment of type 2 diabetes, and an anti-obesity medication used for weight management. It can be administered by subcutaneous injection or tak…
https://en.wikipedia.org/wiki/Semaglutide

menu_book

wikipedia NEUTRAL — Tirzepatide is a gastric inhibitory polypeptide (GIP) analog and a GLP-1 receptor agonist. It is used as an antidiabetic medication to treat type 2 diabetes (T2D) and for weight loss. Tirzepatide is a…
https://en.wikipedia.org/wiki/Tirzepatide

+ 3 more evidence sources

check_circle

Claim 4: “Novo Nordisk, the maker of Ozempic and a pioneer in diabetes and obesity treatments, sued rival Eli Lilly on Tuesday, accusing the U.S. drugmaker of false advertising.”

CORROBORATED

Multiple independent news sources (NBC, FOX 26, ICLG) report that Novo Nordisk sued Eli Lilly over misleading advertising of obesity drugs.

menu_book

+ 3 more evidence sources

check_circle

Claim 5: “SURMOUNT-5 is a clinical trial that compares the weight-loss effects of tirzepatide and semaglutide in adults with obesity, or who are overweight with weight-related health conditions, but without type 2 diabetes.”

CORROBORATED

Multiple sources describe SURMOUNT-5 as evaluating weight loss in adults with obesity or overweight with comorbidities, excluding type 2 diabetes.

travel_explore

web search NEUTRAL — How does weight loss differ between patients receiving tirzepatide compared with semaglutide among a clinical population of adults with overweight or obesity?
https://pmc.ncbi.nlm.nih.gov/articles/PMC11231910/

travel_explore

web search NEUTRAL — SURMOUNT-5Tirzepatide vs Semaglutide for Obesity and Overweight with Comorbidities.This study aims to evaluate whether tirzepatide or semaglutide is more effective in reducing body weight in adults wh…
https://www.patlynk.com/trial/NCT05822830

travel_explore

web search NEUTRAL — "The SURMOUNT-5 head-to-head results demonstrated tirzepatide led to greater weight reduction compared to semaglutide, providing further evidence to support tirzepatide as an effective option for obes…
https://www.appliedclinicaltrialsonline.com/view/tirzepatide…

help

Claim 6: “The company says Lilly instead relied on studies using Wegovy doses of 1.7 mg and 2.4 mg.”

INSUFFICIENT EVIDENCE

No evidence was found in the provided search results to confirm the specific claim that Novo Nordisk alleges Lilly relied on Wegovy doses of 1.7 mg and 2.4 mg in this context.

check_circle

Claim 7: “Novo Nordisk also alleges Eli Lilly's Mounjaro advertisements compare the drug's highest approved dose, 15 mg, with Ozempic's lowest dose, 1 mg, instead of its highest approved dose of 2 mg.”

CORROBORATED

NBC and other reports confirm the allegation that Mounjaro ads compare the 15 mg dose to Ozempic's 1 mg dose instead of the 2 mg dose.

travel_explore

web search NEUTRAL — Novo claims Lilly’s Mounjaro campaign compares the highest 15 mg dose with only the 1 mg dose of Ozempic, instead of its FDA-approved 2 mg maintenance dose. The lawsuit has been filed in the U.S. Dist…
https://stocktwits.com/news-articles/markets/equity/novo-nor…

travel_explore

web search NEUTRAL — Novo Nordisk’s complaint argues that Lilly's campaigns leave out information about the most effective injectable doses of Wegovy (semaglutide) and Ozempic (semaglutide), a dispute that could reshape h…
https://www.pharmaceuticalcommerce.com/view/why-novo-nordisk…

travel_explore

web search NEUTRAL — “Novo Nordisk has never tested its highest doses of semaglutide against Lilly's tirzepatide medicines in any clinical trial; instead, it is using a lawsuit to advance comparisons it has never put to t…
https://www.fiercepharma.com/marketing/novo-turns-heat-lilly…

check_circle

Claim 8: “SURMOUNT-5, which remains the only randomized head-to-head clinical trial directly comparing tirzepatide and semaglutide for weight management”

CORROBORATED

The Guardian, Pallas Health, and other sources report that Eli Lilly identifies SURMOUNT-5 as the only direct, head-to-head randomized clinical trial comparing the two drugs for obesity.

travel_explore

web search NEUTRAL — Eli Lilly responded to its rival’s accusations with a statement saying that the trial which underpins its advertising, known as Surmount-5, is “the only direct, head-to-head randomised clinical trial …
https://www.theguardian.com/business/2026/jul/21/novo-nordis…

travel_explore

web search NEUTRAL — In SURMOUNT-5, the only randomized head-to-head obesity trial, tirzepatide produced 20.2% body weight loss versus 13.7% on semaglutide at 72 weeks in adults with obesity.
https://glp3planner.com/resources/mounjaro-vs-semaglutide

travel_explore

web search NEUTRAL — In the only head-to-head clinical trial comparing the two (SURMOUNT-5), tirzepatide (Zepbound®, 10 mg or 15 mg weekly) produced significantly more weight loss than semaglutide (Wegovy®, 1.7 mg or 2.4 …
https://www.pallashealth.co/blog/semaglutide-vs-tirzepatide

check_circle

Claim 9: “Eli Lilly's Zepbound advertisements comparing the drug with Wegovy rely on outdated comparisons using the maximum tolerated doses of each medication, even though, Novo Nordisk argues, there is no head-to-head clinical trial comparing the highest approved doses of the two drugs.”

CORROBORATED

FOX 26 Houston explicitly quotes the complaint stating there are no head-to-head clinical trials comparing the highest doses of the respective medicines.

menu_book

wikipedia NEUTRAL — Glucagon-like peptide-1 (GLP-1) receptor agonists, also known as GLP-1 agonists, GLP-1RAs, and informally as simply GLP-1s, are a class of medications that activate the GLP-1 receptor, causing reduced…
https://en.wikipedia.org/wiki/GLP-1_receptor_agonist

menu_book

wikipedia NEUTRAL — LifeMD, Inc. is a publicly traded American telehealth company. It gives subscribers access to doctors and nurse practitioners for virtual medical consultations and treatments with prescription medicat…
https://en.wikipedia.org/wiki/LifeMD

menu_book

+ 3 more evidence sources

verified

Claim 10: “The Danish company filed the lawsuit in U.S. District Court in New Jersey”

VERIFIED

A specific web search result explicitly states that the lawsuit was filed in the U.S. District Court for the District of New Jersey.

menu_book

+ 3 more evidence sources

info Disclaimer: This analysis is generated by AI and should be used as a starting point for critical thinking, not as definitive truth. Claims are verified against publicly available sources. Always consult the original article and additional sources for complete context.